Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for active immunotherapy as well as disease prevention. 

In contrast to traditional therapies, the goal of active immunotherapy is to amplify the patients’ ability to fight specific disease rather than targeting the diseased tissue or pathogenic agent directly.  The novel technologies being developed at Antigen Express allows for robust and antigen-specific stimulation of CD4+ T cells, a cell type critical in the recognition of pathogens and modulation of the immune response. 

Antigen Express is developing these technologies for application to the treatment of cancer, infectious diseases, and other serious diseases.  Our most advanced vaccine utilizes a self-potentiating peptide as an off-the-shelf product for active immunotherapy of breast and prostate cancer. 


  ASCO: AE37 Peptide Vaccine May Help Prevent Breast Cancer Recurrence




read more about us

3/26/2014   Generex/Antigen Express Announces Participation on Panel at Upcoming Cancer Immunotherapeutics Symposium
3/5/2014   Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza
2/27/2014   Generex Announces Publication of Biomarker Studies Related to the Antigen Express Novel Immunotherapeutic AE37 in Prostate Cancer Patients

ASCO 2013 - Elizabeth A. Mittendorf, M.D., Ph.D., HER2 Peptide Vaccine


SNNLive Update with Antigen Express

2004 Antigen Express | One Innovation Drive | Worcester, MA 01605
Phone: (508) 852-8783 | Fax: (508) 852 8653 |
Website designed by NRG Networks